Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023)

Ironwood Pharmaceuticals' (IRWD) quarterly Income from Non-Controlling Interests came in at -$658000.0 in Q4 2023, up 52.01% quarter-over-quarter from -$1.4 million in Q3 2023.

Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends

Ironwood Pharmaceuticals has disclosed Income from Non-Controlling Interests across 2 years of filings, most recently posting -$658000.0 for Q4 2023.

  • Income from Non-Controlling Interests for Q4 2023 came in at -$658000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was -$29.3 million (changed N/A YoY), and the FY2023 annual result was -$29.3 million, changed N/A from the prior year.
  • Income from Non-Controlling Interests came in at -$658000.0 for Q4 2023 at Ironwood Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$658000.0 in Q4 2023 to a low of -$27.3 million in Q2 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn -
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn -
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn -
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn 22.56 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn -
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn -
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn -
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn -
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn -
10 Ironwood Pharmaceuticals 546.74 Mn 326.27 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -658,000.00
Sep 30, 2023 -1.37 Mn
Jun 30, 2023 -27.29 Mn
Sep 30, 2010 1.52 Mn
Jun 30, 2010 -73,000.00